Compare Inovio Pharmaceuticals Inc (INO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs MGM Resorts International — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while MGM Resorts International trades at $29.27 (market cap $7.55B). The key difference: MGM Resorts International is far larger — about 67.3× Inovio Pharmaceuticals Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and MGM Resorts International for 91 Days on average.
| INO | MGM | |
|---|---|---|
Market Cap | $112.19M | $7.55B |
Volume | 3,201,278 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $50.69 |
52-Week Low | $0.66 | $30.00 |
Typical Hold Time | 43 Days | 91 Days |
Enterprise Value | $83.51M | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement (+0.03%) amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock faces bearish technical signals with oversold RSI readings, while fundamentals show mixed results with Q2 2026 earnings beating expectations but net margins declining to 2.4% in 2025. Recent news highlights potential MGM interest in acquiring People Inc., creating uncertainty around strategic direction.
MGM presents a value opportunity with P/S ratio of 0.45 below industry averages, supported by strong analyst consensus ($48.75 price target, 51% buy ratings). However, risks include declining profit margins, failed acquisition attempts, and ongoing debt burden. The stock's current discount to analyst targets suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
